跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

L-021

Supelco

Lorazepam glucuronide solution

100 μg/mL in acetonitrile: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C21H18Cl2N2O8
CAS号:
32781-79-6
分子量:
497.28
MDL编号:
MFCD02682126
UNSPSC代码:
41116107
PubChem化学物质编号:
329817344
NACRES:
NA.24

等级

certified reference material

质量水平

300

形式

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland)

浓度

100 μg/mL in acetonitrile: water (1:1)

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

clinical testing

格式

single component solution

储存温度

−20°C

SMILES字符串

O[C@@H]1[C@@H](O)[C@H](OC2N=C(c3ccccc3Cl)c4cc(Cl)ccc4NC2=O)O[C@@H]([C@H]1O)C(O)=O

InChI

1S/C21H18Cl2N2O8/c22-8-5-6-12-10(7-8)13(9-3-1-2-4-11(9)23)25-19(18(29)24-12)33-21-16(28)14(26)15(27)17(32-21)20(30)31/h1-7,14-17,19,21,26-28H,(H,24,29)(H,30,31)/t14-,15-,16+,17-,19?,21-/m0/s1

InChI key

IWOJSSFCRQKNKN-IFBJMGMISA-N

相关类别

一般描述

Lorazepam glucuronide is a primary urinary metabolite of lorazepam, a benzodiazepine often prescribed for treatment of anxiety disorders. This Certified Spiking Solution® is suitable for use as starting material in calibrators or controls for a variety of LC/MS or GC/MS applications from clinical toxicology and forensic analysis to urine drug testing.

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

相关产品

产品编号
说明
价格

B-033

8种苯二氮卓类混标 CRM 溶液, 250 μg/mL each component in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

L-901

劳拉西泮标准液 溶液, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

L-902

劳拉西泮-D4标准液 CRM 溶液, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

L-907

氯甲西泮标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

L-911

劳拉西泮-D4标准液 CRM 溶液, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

D-163

地洛西泮-D4 溶液, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

L-059

Lorazepam-D4 glucuronide lithium salt solution, 100 μg/mL (Acetonitrile:Water (50:50) (v/v), (as free acid)), certified reference material, ampule of 1 mL, Cerilliant®

象形图

FlameExclamation mark
GHS02,GHS07

警示用语：

Danger

危险声明

H225,H302,H319

危险分类

Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

WGK

WGK 2

闪点(°F)

55.4 °F

闪点(°C)

13 °C

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

R Verbeeck et al.
British journal of clinical pharmacology, 3(6), 1033-1039 (1976-12-01)
To evaluate the effect of end-stage renal insufficiency and haemodialysis on the elimination of lorazepam, single oral doses of the drug (2.5 mg) were administered to normal subjects and patients with chronic renal failure (CC(r) : less than 2 ml/min)
In vitro binding of lorazepam and lorazepam glucuronide to cholestyramine, colestipol, and activated charcoal.
R J Herman et al.
Pharmaceutical research, 8(4), 538-540 (1991-04-01)
A J Cummings et al.
British journal of clinical pharmacology, 12(4), 511-515 (1981-10-01)
1 An investigation has been made of the excretion of alpha-methyldopa, alpha-methyldopa sulphate, lorazepam and lorazepam glucuronide in the urine of neonates. 2 The rate of elimination of both the drugs in the newborn is slow compared with the adult
R A Branch et al.
The Journal of laboratory and clinical medicine, 102(5), 805-812 (1983-11-01)
The relative effects of pretreatment with allyl alcohol and carbon tetrachloride on oxidative and glucuronide metabolism of lorazepam have been compared in the isolated perfused rat liver. Livers from rats pretreated for 24 hr with allyl alcohol (1.8 ml/kg, 1:50
Eleonora L Swart et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 45(2), 360-371 (2005-02-03)
The objective is to study the population pharmacokinetics of lorazepam and midazolam in critically ill patients with acute renal failure who are treated with continuous venovenous hemofiltration (CVVH). Twenty critically ill patients with acute renal failure on CVVH therapy were
查看所有相关文献

实验方案

使用UHPLC/MS（TOF）检测不同酶水解条件处理的尿液中药物和代谢物

为了使用β-葡糖醛酸酶优化水解，必须对每种待分析的葡糖苷酸代谢物进行某些因素的评估，例如孵育时间、温度、水解pH、酶源和酶浓度。

UHPLC/MS for Drug Detection in Urine

Optimize β-glucuronidase hydrolysis for glucuronide metabolite analysis considering factors like time, temperature, pH, and enzyme concentration.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门